Previous studies have shown for tumor cells that co-treatment with this drug concentration effectively abolishes the upregulation of ERK1/2 phosphorylation induced by BRAF inhibitors alone (King et al., 2013). This evidence concerns the gene MAPK3 and neoplasm.